Guardant Health (NASDAQ: GH) reported Q3 EPS of ($0.39), $0.40 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $265.2 million versus the consensus estimate of $235.64 million.

GUIDANCE:

Guardant Health sees Q4 2025 revenue of $935-970 million, versus the consensus of $922 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.